NSE: INDOCO | BSE: 532612

Momentum Trap

Download real time

310.70 -6.80 (-2.14%)

63.53% Gain from 52W Low

40,223 NSE+BSE Volume

NSE 22 Jul, 2025 3:31 PM (IST)

2,866.1

Market Cap

Above industry Median

0.8

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Indoco Remedies Ltd. is on 24 Jul 2025 for the purpose of Quarterly Results See details

Indoco Remedies Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for INDOCO, BSE:532612 Indoco Remedies Ltd.

Indoco Remedies Ltd.

24 Nov 2017

310.70

-2.14%

Result Updates

Sell: Indoco Remedies Ltd.

Target

Angel Broking

For 2QFY2018 Indoco Remedies sales came in at `280cr, in line with expectations, posting a yoy growth of 1.3%. The growth was impacted by lower exports, mainly on the back of US (` post a 69.5% yoy dip in sales). Indian Formulation sales posted 11.5% yoy growth. On operating front, the EBITDA margins came in at 12.9% (11.8% expected)...

Indoco Remedies Ltd. is trading above all available SMAs

Indoco Remedies Ltd.

09 Nov 2017

310.70

-2.14%

Indoco Remedies

Hold: Indoco Remedies Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues remained flat YoY at | 285 crore (I-direct estimate: | 291 crore). Export formulations declined 20% YoY to | 74 crore (I-direct estimate: | 94 crore) while domestic formulations grew 12% to | 188 crore (I-direct estimate: | 177 crore) EBITDA margins declined 56 bps YoY to 14.4% (I-direct estimate of 14.2%) mainly on account of lower gross margins (64.8% in Q2FY18 vs. 65.5% in Q2FY17). EBITDA declined 2.4% YoY to | 41 crore (Idirect estimate: | 41 crore)...

Indoco Remedies Ltd. has gained 27.77% in the last 3 Months

Indoco Remedies Ltd.

14 Aug 2017

310.70

-2.14%

Result Updates

Sell: Indoco Remedies Ltd.

Target

Angel Broking

For 1QFY2018 Indoco Remedies posted poor set of numbers. Sales came in at `204cr (`214cr expected) v/s. `253cr in 1QFY2017, a yoy de-growth of 19.1%. The company witnessed a disruptive 1QFY2018, with domestic as well International sales getting affected adversely due to GST implementation in India and voluntary stoppage of ophthalmic prod..

Indoco Remedies Ltd. has gained 27.77% in the last 3 Months

Indoco Remedies Ltd.

11 Aug 2017

310.70

-2.14%

Indoco Remedies

Hold: Indoco Remedies Ltd.

Recommendation Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues declined 19% YoY to | 209 crore (I-direct estimate: | 242 crore). Export formulations declined 11% YoY to | 86 crore (I-direct estimate: | 95 crore) and domestic formulations declined 30% to | 100 crore (I-direct estimate: | 121 crore) EBITDA margins fell 1580 bps YoY to 0.6% (I-direct estimate of 11%) mainly due to higher employee and other expenditure. EBITDA declined 97% YoY to | 1.3 crore (I-direct estimate: | 27 crore)...

Indoco Remedies Ltd. has gained 27.77% in the last 3 Months

Indoco Remedies Ltd.

12 Jun 2017

310.70

-2.14%

Result Updates

Sell: Indoco Remedies Ltd.

Target

Angel Broking

Indoco Remedies posted lower than expected numbers for 4QFY2017. In sales, the company posted revenues of `266cr (`311cr expected) v/s. `255cr in 4QFY2016, growth of 4.2% yoy. The formulation business posted sales of `251.6cr, up 3.3% yoy, while API at `12.0cr was down 4.7% yoy. The domestic formulation at `130.1cr recorded a yoy de-growt..

Indoco Remedies Ltd. has an average target of 320.00 from 2 brokers.

Indoco Remedies Ltd.

03 Apr 2017

310.70

-2.14%

Indoco Remedies

Buy: Indoco Remedies Ltd.

Target

ICICI Securities Limited

The USFDA has issued Indoco Remedies a warning letter for its Goa manufacturing facilities: unit 2 and 3. The warning letter was served to the company, following the USFDA inspection carried out during August 31September 4, 2016, for which Indoco had been issued six observations. These two units are located in the same complex and have been issued the same warning letter. Both facilities have been inspected five times by the USFDA since 2005. The USFDA has accepted five responses from the company but remains critical regarding the sixth response, which pertains to the leakage issue in a few products, especially for ophthalmic...

Indoco Remedies Ltd. is trading above all available SMAs

Is Indoco Remedies Ltd. worth buying?

60 Votes:

Buy 75.0%

Sell 15.0%

Hold 10.0%

RESEARCH REPORTS

Not Rated SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf